News

Initiating and adhering to ART is a difficult task for a significant number of people living with HIV. A new study shows that making a concerted effort to find and encourage this population to get the care they need is not an impossible dream.

Efforts to understand the rare polio-like condition acute flaccid myelitis got a boost from the NIAID, which awarded $10 million over 5 years for a natural history study.

The new recommendations aim to limit the potentially deadly disease from infecting newborns or mothers.

August 1, 2019, marks the 1 year anniversary of the North Kivu Ebola outbreak.

As July draws to a close, the Contagion® editorial team is recapping the trends and top infectious disease news of the month.

The adjusted hazard ratios for 1-dose and 2-dose recipients were comparable to the 3-dose recipients (1 dose 1.01 [95%CI 0.81–1.26], 2 doses 1.00 [0.85–1.17]) after adjusting for age at vaccination among the vaccinated group.

The disease remains endemic in the region but an increase in confirmed cases since the start of the year has raised concern.

Public health officials are growing increasingly concerned about the health dangers of medical misinformation. However, it’s proving to be an especially difficult problem to solve.

Knee and hip replacement patients who have healthier intestinal microflora may have a lower risk of developing dangerous periprosthetic joint infections than patients with unhealthy guts.

Deeper understanding of how Yersinia plague pathogens impede the immune system could help investigators develop targeted treatments for these bacterial infections.

Not all disinfectants are created equal and here's why we need to remember that.

As of July 24, 2019, 132 individuals have been diagnosed with Cyclospora infection as part of a multistate outbreak linked to consumption of fresh basil.

The percentage of participants who achieved HIV-1 RNA< 50 copies/mL in the 0.25 mg, 0.75 mg, 2.25 mg MK-8591 dose groups was 89.7%, 90.0%, and 77.4%, respectively, at week 48.

A sharp increase in syphilis cases in Europe is hitting hardest among MSM and has been linked to the use of PrEP drugs and an increase in risky sexual behavior.

Providers’ communication styles and level of knowledge about HIV have a significant impact on whether patients begin and remain in treatment.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of July 21, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

At week 48, 83.8% of participants in the TAF/FTC/DTG arm had HIV RNA < 50 copies/mL, 84.9% for TDF/FTC/DTG and 78.6% for TDF/FTC/EFV.

GEMINI 1 & 2 are phase 3, randomized, double-blind, multicenter studies evaluating the 2-drug regimen of DTG/3TC in comparison with the 3-drug regimen of DTG + TDF/FTC.

The final results of HOPE, a phase 3 open-label extension trial, show high uptake and lower-than-anticipated HIV-1 incidence.

The discovery of dendritic cells known as CD11c+ offers a pathway to understanding the mechanism behind HIV transmission and how to halt it.

New results indicate that the study met its primary end point for non-inferiority based on the proportion of participants with plasma HIV-1 RNA > 50 copies per mL at week 48.

The investigators observed durable humoral immune responses over 2 years with a response rate of 100% in participants receiving the Ad26.Mos.HIV, gp140HD vaccine regimen.

With 1329.6 person-years of PrEP use accumulated, early continuation was achieved by 79.8% of participants.

We're separating fact from fiction regarding the investigation into these concerns.

The phase 2a study compares a bivalent combination of Clade C and Mosaic gp140 with a single-valent Clade C gp140.

Providers who received the intervention materials had higher satisfaction and confidence in prescribing chronic opioid therapy than their colleagues who did not.